Google
XRTX 株価分析 — XORTX THERAPEUTICS INC (Healthcare >> Biotechnology)
XRTX に関するよくある質問
XRTXのROE（自己資本利益率）は？
XORTX THERAPEUTICS INCのROEは-214.76%です。
XRTXの配当利回りは？
XORTX THERAPEUTICS INCの配当利回りは0.00%です。
XRTXの品質スコア（Quality Score）は？
当社のAIはXRTXの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
XRTXは今が買い時ですか？
当社AIのタイミングスコアは100点中3点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
XRTXはどのセクターに属しますか？
XORTX THERAPEUTICS INCはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
XRTX AI Analysis Summary
Our AI summary for XRTX: XORTX THERAPEUTICS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -214.76%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 3/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 2.12
Price
0.10
(4.95%)
Day Change
|
|
|---|
XRTX, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.12 |
| PBV / Sector |
2.71 / 5.20
|
| Earning Per Share | -1.68 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
0.03 M
GREAT
|
| Average 1W Daily Value |
0.03 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:43 |
| Symbol | XRTX |
| Name | XORTX THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 1.73 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3.50 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3710 - 33rd Street NW, Calgary, AB, Canada, T2L 2M1
Phone: 403-455-7727
Website: https://www.xortx.com
Sector: Healthcare >> Biotechnology
Description: XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
